靶向酪蛋白水解线粒体基质肽酶:高危多发性骨髓瘤病理生物学的新贡献因素
研究通过单细胞转录组学发现,酪蛋白水解蛋白酶水解亚基(CLPP)在CD138+肿瘤性浆细胞较正常浆细胞、症状性骨髓瘤较前驱期浆细胞中过表达,其高表达与多发性分子亚组不良预后及髓外疾病相关。药理学抑制和遗传抑制CLPP可降低类器官生长、细胞活力和细胞周期进展,并诱发未折叠蛋白反应和凋亡,与线粒体跨膜电位丢失及半胱天冬酶和蛋白酶体激活相关,呈活性氧依赖方式。CLPP抑制可克服传统和新型药物耐药,在原代样本中诱导凋亡,体内显示疗效,并可通过临床相关药物inobrodib实现;CLPP与蛋白酶体抑制剂联合方案显示增强疗效。
要点
- CLPP在CD138+肿瘤性浆细胞较正常浆细胞、症状性骨髓瘤较前驱期浆细胞中过表达。
- CLPP高表达与新诊断和复发/难治背景下多个分子亚组的不良预后及髓外疾病相关。
- CLPP抑制可降低类器官生长、细胞活力和细胞周期进展,并诱导未折叠蛋白反应和凋亡。
核心结论
- CLPP是转化浆细胞的关键贡献因素、高危行为的新型介质,也是骨髓瘤治疗的合理靶点,其抑制剂可与当前治疗合理联合以改善结局。
研究设计与样本
- 研究采用单细胞转录组学,比较CD138+肿瘤性浆细胞与正常浆细胞、症状性骨髓瘤与 precursor 浆细胞中CLPP的表达。
主要发现
- CLPP在CD138+肿瘤性浆细胞较正常浆细胞、症状性骨髓瘤较前驱期浆细胞中过表达。
- CLPP高表达与新诊断和复发/难治背景下多个分子定义亚组的不良预后及髓外疾病相关。
- 药理学CLPP抑制和遗传抑制降低类器官生长、细胞活力和细胞周期进展,并触发未折叠蛋白反应和凋亡。
- CLPP抑制与线粒体跨膜电位丢失及半胱天冬酶和蛋白酶体激活相关,呈活性氧依赖方式。
- 下游效应包括诱导自噬和线粒体自噬,以及氧化磷酸化和糖酵解减少,导致线粒体和胞质三磷酸腺苷(ATP)产生受损。
关键数值与推荐
- CLP内肽酶抑制可克服传统和新型药物耐药,在原代样本中诱导凋亡,体内显示疗效,并可通过临床相关药物inobrodib实现。
- CLPP与蛋白酶体抑制剂联合方案显示增强疗效,与中间代谢和自噬抑制剂联合方案同样显示增强疗效。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Plasma cell dyscrasias encompass a spectrum from the precursors monoclonal gammopathy of undetermined significance and smoldering myeloma to symptomatic myeloma, but the genes that enable progression and confer poor prognosis are incompletely understood. Using single-cell transcriptomics, we identified the caseinolytic protease proteolytic subunit (CLPP), a key component of the mitochondrial caseinolytic protease (CLP) serine endopeptidase, as being overexpressed in CD138+ neoplastic vs normal and in symptomatic vs precursor plasma cells. Its high expression was associated with an adverse prognosis across multiple molecularly defined subgroups in the newly diagnosed and relapsed/refractory settings and with extramedullary disease. Pharmacologic CLPP inhibition and genetic suppression reduced organoid growth, cell viability, and cell cycle progression, and triggering an unfolded protein response and apoptosis. This occurred in association with mitochondrial transmembrane potential loss and caspase and proteasome activation in a reactive oxygen species-dependent manner. Downstream consequences included autophagy and mitophagy induction and reductions in oxidative phosphorylation and glycolysis with consequent compromise of mitochondrial and cytoplasmic adenosine triphosphate (ATP) production. CLP endopeptidase inhibition overcame conventional and novel drug resistance, induced apoptosis in primary samples, showed efficacy in vivo, and could be achieved with the clinically relevant agent inobrodib. Finally, regimens combining a CLPP and proteasome inhibitor showed enhanced efficacy, as did combinations with inhibitors of intermediary metabolism and autophagy. Taken together, our data indicate that CLPP is a key contributor to transformed plasma cells, a novel mediator of high-risk behavior, and a legitimate target for myeloma therapy whose inhibitors could be rationally combined with current therapeutics to improve outcomes.
引用
- Qin L, Moreno Rueda LY, Ray U, et al. Targeting caseinolytic mitochondrial matrix peptidase, a novel contributor to the pathobiology of high-risk multiple myeloma. Blood. 2025. PMID: 39912779. doi:10.1182/blood.2024024781
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。